Summary

Early drug development requires adherence to Good Manufacturing Practices (GMP) guidelines when manufacturing investigational medicinal products (IMPs) for clinical studies conducted within Europe. Studies which are directly supported by GMP-compliant on-site manufacturing facilities add substantial value by significantly cutting costs and timelines through proven, efficiency-focused processes.

Register to download

Onsite Manufacturing Early Clinical Development

You may also be interested in: